Neuland Laboratories Limited has announced that its management will participate in a group analyst and institutional investor meeting on June 5, 2026. The meeting is part of the BOFA Healthcare Tour and will take place in Hyderabad. This engagement provides a platform for the company to interact with key market stakeholders and discuss its performance and strategy.

The disclosure was made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was addressed to BSE Limited and The National Stock Exchange of India Ltd to ensure compliance with regulatory requirements.

The meeting format includes both group and one-on-one sessions, allowing for detailed discussions with participants. The company noted that the schedule and participant list are subject to change due to any exigencies on the part of the participants or the company.

Sarada Bhamidipati, Company Secretary of Neuland Laboratories Limited, signed the intimation on May 31, 2026. The company's scrip codes are 524558 on BSE and NEULANLAB on NSE.

neuland laboratories has intimated that its management will participate in the 360 ONE Capital 16th Annual Investor Conference - TRINITY INDIA 2026. The disclosure was made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The event is scheduled to take place on May 28, 2026, in Mumbai. The company's management will engage with analysts and institutional investors through both group meetings and one-on-one sessions.

Meeting Details

The following table outlines the specifics of the upcoming investor meeting:

The company noted that the schedule and participant list for the meeting are subject to change due to any exigencies on the part of the participants or the company. This information has been submitted to the stock exchanges for their records.